Core Viewpoint - The company reported a decline in revenue and profit for the year 2025, primarily due to challenges in its automotive mold components business, which faced increased costs and competitive pressures [14]. Financial Performance - The company achieved an operating revenue of 315 million yuan, a year-on-year decrease of 9.15% [14]. - The net profit attributable to shareholders was 7.81 million yuan, down 43% year-on-year [14]. - The net profit after deducting non-recurring items was 1.91 million yuan, a decline of 79% [14]. - Basic earnings per share were 0.06 yuan, with a weighted average return on equity of 1.42%, down 1.07 percentage points from the previous year [14]. Valuation Metrics - As of the closing price on February 27, the company's price-to-earnings (P/E) ratio (TTM) was approximately 339.31 times, the price-to-book (P/B) ratio (LF) was about 4.8 times, and the price-to-sales (P/S) ratio (TTM) was around 7.87 times [14]. Industry Context - The company operates in the specialized equipment manufacturing sector, specifically within the mold manufacturing industry [14]. - The automotive mold components business faced significant operational pressure due to increased procurement costs from imported raw materials and intensified domestic market competition, leading to a decline in sales and revenue [14]. - Despite growth in the medical device components and automation components segments, this growth was insufficient to offset the decline in the automotive mold components business, resulting in an overall decrease in performance [14].

Performance Forecast - The company has voluntarily announced a performance forecast for the period from January 1, 2025, to December 31, 2025, indicating a projected decline in performance [1] - The company expects a year-on-year revenue decline of approximately 9% due to operational pressures in its main automotive mold components business [1] Reasons for Performance Change - The decline in revenue is attributed to increased procurement costs from imported raw materials due to tariff hikes, coupled with intensified competition in the domestic automotive mold components market, leading to reduced sales and revenue [1] - Although the medical device components and automation components segments experienced year-on-year growth, this growth was insufficient to offset the decline in the automotive mold components business, resulting in an overall decrease in performance [1] Financial Risk Management - The company is focusing on financial risk prevention by enhancing the management of accounts receivable, implementing a customer credit assessment mechanism, and strengthening the tracking of payment processes, with no significant bad debts reported during the period [2] Additional Information - The performance forecast is based on preliminary calculations by the company's finance department and has not yet been audited [3] - Detailed performance data for 2025 will be disclosed in the company's annual report for that year [3]